This review summarizes the various challenges in product development involved in subcutaneous administration of high-dose monoclonal antibodies and attempts to provide an industry perspective of some of the available technologies and potential avenues to overcome these challenges.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/tde.12.68 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!